Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
22 11 2022
22 11 2022
Historique:
received:
01
03
2022
accepted:
01
07
2022
pubmed:
20
9
2022
medline:
24
11
2022
entrez:
19
9
2022
Statut:
ppublish
Résumé
Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There are limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors. This is a secondary analysis of the ACTION-CVT study which is a multicenter international study of consecutive patients hospitalized with a diagnosis of CVT over a 6-year period. Patients with cancer-associated CVT, CVT during pregnancy, or CVT in the setting of known antiphospholipid antibody syndrome were excluded per the ACTION-CVT protocol. The study outcome was recurrent venous thrombosis defined as recurrent venous thromboembolism (VTE) or de novo CVT. We compared characteristics between patients with vs without recurrent venous thrombosis during follow-up and performed adjusted Cox regression analyses to determine important predictors of recurrent venous thrombosis. Nine hundred forty-seven patients were included with a mean age of 45.2 years, 63.9% were women, and 83.6% had at least 3 months of follow-up. During a median follow-up of 308 (interquartile range 120-700) days, there were 5.05 recurrent venous thromboses (37 VTE and 24 de novo CVT) per 100 patient-years. Predictors of recurrent venous thrombosis were Black race (adjusted hazard ratio [aHR] 2.13, 95% CI 1.14-3.98, Black race, history of VTE, and the presence of one or more antiphospholipid antibodies are associated with recurrent venous thrombosis among patients with CVT. Future studies are needed to validate our findings to better understand mechanisms and treatment strategies in patients with CVT.
Sections du résumé
BACKGROUND AND OBJECTIVE
Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There are limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors.
METHODS
This is a secondary analysis of the ACTION-CVT study which is a multicenter international study of consecutive patients hospitalized with a diagnosis of CVT over a 6-year period. Patients with cancer-associated CVT, CVT during pregnancy, or CVT in the setting of known antiphospholipid antibody syndrome were excluded per the ACTION-CVT protocol. The study outcome was recurrent venous thrombosis defined as recurrent venous thromboembolism (VTE) or de novo CVT. We compared characteristics between patients with vs without recurrent venous thrombosis during follow-up and performed adjusted Cox regression analyses to determine important predictors of recurrent venous thrombosis.
RESULTS
Nine hundred forty-seven patients were included with a mean age of 45.2 years, 63.9% were women, and 83.6% had at least 3 months of follow-up. During a median follow-up of 308 (interquartile range 120-700) days, there were 5.05 recurrent venous thromboses (37 VTE and 24 de novo CVT) per 100 patient-years. Predictors of recurrent venous thrombosis were Black race (adjusted hazard ratio [aHR] 2.13, 95% CI 1.14-3.98,
DISCUSSION
Black race, history of VTE, and the presence of one or more antiphospholipid antibodies are associated with recurrent venous thrombosis among patients with CVT. Future studies are needed to validate our findings to better understand mechanisms and treatment strategies in patients with CVT.
Identifiants
pubmed: 36123126
pii: WNL.0000000000201122
doi: 10.1212/WNL.0000000000201122
pmc: PMC9687409
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2368-e2377Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 American Academy of Neurology.
Références
Stroke. 2011 Apr;42(4):1158-92
pubmed: 21293023
N Engl J Med. 2010 Dec 23;363(26):2499-510
pubmed: 21128814
Lupus. 2011 Feb;20(2):206-18
pubmed: 21303837
Blood. 2018 Sep 27;132(13):1365-1371
pubmed: 30002145
Blood Cells Mol Dis. 2006 Sep-Oct;37(2):100-6
pubmed: 16889993
Stroke. 2004 Mar;35(3):664-70
pubmed: 14976332
Stroke. 2012 Dec;43(12):3375-7
pubmed: 22996960
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104987
pubmed: 32689593
N Engl J Med. 2005 Apr 28;352(17):1791-8
pubmed: 15858188
N Engl J Med. 2020 Apr 23;382(17):1599-1607
pubmed: 32223112
Stroke. 2022 Mar;53(3):728-738
pubmed: 35143325
Cerebrovasc Dis. 2005;19(3):147-51
pubmed: 15644626
N Engl J Med. 2013 Aug 29;369(9):799-808
pubmed: 23808982
Lancet Neurol. 2007 Feb;6(2):162-70
pubmed: 17239803
Cochrane Database Syst Rev. 2018 Jan 24;1:CD006649
pubmed: 29363105
Chest. 2012 Feb;141(2 Suppl):e152S-e184S
pubmed: 22315259
N Engl J Med. 2009 Dec 10;361(24):2342-52
pubmed: 19966341
JAMA. 1997 Apr 23-30;277(16):1305-7
pubmed: 9109469
Can Fam Physician. 2017 Oct;63(10):e425-e431
pubmed: 29025819
Stroke. 2020 Nov;51(11):3425-3432
pubmed: 33104466
Stroke. 2020 Nov;51(11):3406-3416
pubmed: 33104476
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Stroke. 2016 Sep;47(9):2180-2
pubmed: 27435401
J Thromb Haemost. 2012 Jul;10(7):1297-302
pubmed: 22578023
Neurology. 2020 Oct 20;95(16):e2200-e2213
pubmed: 32847952
Neurology. 2019 Oct 29;93(18):e1664-e1674
pubmed: 31554649
J Thromb Haemost. 2020 Feb;18(2):411-421
pubmed: 31630479
Stroke. 2010 Sep;41(9):1901-6
pubmed: 20634477
Stroke. 2022 Mar;53(3):663-669
pubmed: 35168369
Stroke. 2017 Feb;48(2):321-326
pubmed: 27980127
Health Inf Manag. 2020 Jan;49(1):58-61
pubmed: 30563370
Br J Haematol. 2012 Apr;157(1):47-58
pubmed: 22313321
JAMA Neurol. 2019 Dec 1;76(12):1457-1465
pubmed: 31479105
Lancet Haematol. 2016 Sep;3(9):e426-36
pubmed: 27570089
Circulation. 2010 Jun 29;121(25):2740-6
pubmed: 20547928
Stroke. 2020 Apr;51(4):1064-1069
pubmed: 32078475
Neurohospitalist. 2016 Oct;6(4):147-150
pubmed: 27695595